Compare NOW & GSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NOW | GSK |
|---|---|---|
| Founded | 2004 | 1715 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 107.2B | 96.1B |
| IPO Year | 2012 | N/A |
| Metric | NOW | GSK |
|---|---|---|
| Price | $113.35 | $52.45 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 31 | 2 |
| Target Price | ★ $202.70 | N/A |
| AVG Volume (30 Days) | ★ 13.6M | 4.5M |
| Earning Date | 04-22-2026 | 04-29-2026 |
| Dividend Yield | N/A | ★ 3.37% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.67 | N/A |
| Revenue | ★ $1,933,026,000.00 | N/A |
| Revenue This Year | $21.52 | $6.81 |
| Revenue Next Year | $18.41 | $4.74 |
| P/E Ratio | $68.19 | ★ $32.75 |
| Revenue Growth | ★ 39.02 | N/A |
| 52 Week Low | $98.00 | $32.38 |
| 52 Week High | $1,057.39 | $61.70 |
| Indicator | NOW | GSK |
|---|---|---|
| Relative Strength Index (RSI) | 39.85 | 35.65 |
| Support Level | $98.59 | $47.89 |
| Resistance Level | $124.66 | $60.37 |
| Average True Range (ATR) | 4.77 | 0.97 |
| MACD | 3.22 | -0.67 |
| Stochastic Oscillator | 42.38 | 11.37 |
ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management, expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service.
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.